SCHEMBL9980128

SCHEMBL9980128

Cc1ccc2c3c(ccc2c1)-c1ccc(C(C)C)cc1OC3

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.35
PGR P06401 2/20 0.34
SIRT2 Q8IXJ6 5/20 0.33
CYP1A2 P05177 3/20 0.33
CYP2A6 P11509 3/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KLK7 P49862 1/20 0.31
CTRC Q99895 1/20 0.31
DHODH Q02127 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2756468 0.95 LMNA (0.35) LMNAPGRSIRT2CYP1A2CYP2A6
SCHEMBL2705798 0.92 LMNA (0.35) LMNAPGRKDM4EMEN1USP2
SCHEMBL2756788 0.90 DHODH (0.36) LMNAPGRSIRT2CYP1A2CYP2A6
SCHEMBL14985628 0.87 KDM4E (0.39) LMNAPGRSIRT2CYP1A2CYP2A6
SCHEMBL9980113 0.86 ESR1 (0.35) LMNACYP1A2CYP2A6KDM4EALDH1A1
SCHEMBL2756786 0.86 ESR1 (0.35) LMNACYP1A2CYP2A6KDM4EALDH1A1
SCHEMBL12676885 0.84 MEN1 (0.32) KDM4EALDH1A1MEN1USP2CYP3A4
SCHEMBL2705599 0.83 KDM4E (0.35) LMNAKDM4EMEN1USP2CYP3A4
SCHEMBL17656255 0.83 PGR (0.32) PGRKDM4EALDH1A1GAAHPGD
SCHEMBL10278824 0.81 DHODH (0.41) LMNAPGRSIRT2CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669234-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2014-03-11 US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157404-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 LMNA 1353/4885PGR 4048/4885SIRT2 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.